• Tuesday, Dec 01, 2020
  • Last Update : 03:09 am

Avigan shown to be effective in Japanese Phase-3 trial for Covid-19

  • Published at 01:28 pm September 23rd, 2020
Avigan Covid-19
File photo: Tablets of Avigan (generic name : Favipiravir), developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co, are displayed during a photo opportunity at Fujifilm's headquarters, in Tokyo on October 22, 2014 Reuters

Avigan acts on the RNA of viruses, inhibiting their ability to replicate

Fujifilm Holdings Corp said on Wednesday a late-stage study of its antiviral drug Avigan showed it reduced recovery times for Covid-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.

The Phase 3 clinical study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group. Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release.

The announcement sent Fujifilm shares up more than 4% in Tokyo to their highest level in four months.

Former Japanese Prime Minister Shinzo Abe had touted Avigan's potential as Japan's contribution to a global race for coronavirus treatments, aiming for domestic approval in May.

The government called on Fujifilm to triple national stockpiles of Avigan, approved in 2014 as an emergency flu treatment, and pledged to donate it to countries on request.

But a lack of patients in Japan hampered clinical testing. In July, researchers at Fujita Health University said their Avigan study failed to reach statistically significant results.

In its statement, Fujifilm said it would perform further analysis of the trial data and seek to file for approval of Avigan for use in Covid-19 as early as October.

This week, the Nikkei newspaper cited ministry sources as saying approval could be granted within a month of receiving such a request.

In July, Fujifilm sold its global rights to Avigan to India's Dr Reddy's Laboratories. Already available generically in many countries under the name favipiravir, the drug has been approved to treat Covid-19 in India and Russia.

Avigan acts on the RNA of viruses, inhibiting their ability to replicate. It is the subject of dozens of trials worldwide, but concerns remain over birth defects it caused in animal studies.

53
52
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail